breakthrough alzheimer's treatment they have been working on exclusive interview with eisai ceo ivan chung. >> tyler, thanks so much ivan, thanks for being with us on a big day tell us what your expectations are for the access of patients and the uptake of this drug is going to look like in the earliest days. as of right now, we know there's no medicare coverage just yet. >> thank you, meg, for having m on the show. this is an important and humble day for the alzheimer's disease community. as you said, yes, this is an accelerated approval for the cms policy restrictions will be here for access for the medicare beneficiaries until full from additional approval can be granted, and that's exactly why, meg, as you and i speak now, the eisai team is working hard to file the application for full traditional approval here friday evening, so that as soon as possible upon the full traditional approval by the fda, we can work with the cms to grant broad access for medicare beneficiaries. >> so you say they're working on it right now when do you expect that full approval application actually to be in